Cargando…

Anhedonia and Depressive Disorders

Anhedonia is a core symptom of depression and of several psychiatric disorders. Anhedonia has however expanded from its original definition to encompass a spectrum of reward processing deficits that received much interest in the last decades. It is a relevant risk factor for possible suicidal behavi...

Descripción completa

Detalles Bibliográficos
Autor principal: Serretti, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Neuropsychopharmacology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335915/
https://www.ncbi.nlm.nih.gov/pubmed/37424409
http://dx.doi.org/10.9758/cpn.23.1086
_version_ 1785071097140477952
author Serretti, Alessandro
author_facet Serretti, Alessandro
author_sort Serretti, Alessandro
collection PubMed
description Anhedonia is a core symptom of depression and of several psychiatric disorders. Anhedonia has however expanded from its original definition to encompass a spectrum of reward processing deficits that received much interest in the last decades. It is a relevant risk factor for possible suicidal behaviors, and that it may operate as an independent risk factor for suicidality apart from the episode severity. Anhedonia has also been linked to inflammation with a possible reciprocal deleterious effect on depression. Its neurophysiological bases mainly include alterations in striatal and prefrontal areas, with dopamine being the most involved neurotransmitter. Anhedonia is thought to have a significant genetic component and polygenic risk scores are a possible tool for predicting an individual’s risk for developing anhedonia. Traditional antidepressants, such as selective serotonin reuptake inhibitors, showed a limited benefit on anhedonia, also considering their potential pro-anhedonic effect in some subjects. Other treatments may be more effective in treating anhedonia, such as agomelatine, vortioxetine, ketamine and transcranial magnetic stimulation. Psychotherapy is also widely supported, with cognitive-behavioral therapy and behavioral activation both showing benefit. In conclusion, a large body of evidence suggests that anhedonia is, at least partially, independent from depression, therefore it needs careful assessment and targeted treatment.
format Online
Article
Text
id pubmed-10335915
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Korean College of Neuropsychopharmacology
record_format MEDLINE/PubMed
spelling pubmed-103359152023-08-31 Anhedonia and Depressive Disorders Serretti, Alessandro Clin Psychopharmacol Neurosci Review Anhedonia is a core symptom of depression and of several psychiatric disorders. Anhedonia has however expanded from its original definition to encompass a spectrum of reward processing deficits that received much interest in the last decades. It is a relevant risk factor for possible suicidal behaviors, and that it may operate as an independent risk factor for suicidality apart from the episode severity. Anhedonia has also been linked to inflammation with a possible reciprocal deleterious effect on depression. Its neurophysiological bases mainly include alterations in striatal and prefrontal areas, with dopamine being the most involved neurotransmitter. Anhedonia is thought to have a significant genetic component and polygenic risk scores are a possible tool for predicting an individual’s risk for developing anhedonia. Traditional antidepressants, such as selective serotonin reuptake inhibitors, showed a limited benefit on anhedonia, also considering their potential pro-anhedonic effect in some subjects. Other treatments may be more effective in treating anhedonia, such as agomelatine, vortioxetine, ketamine and transcranial magnetic stimulation. Psychotherapy is also widely supported, with cognitive-behavioral therapy and behavioral activation both showing benefit. In conclusion, a large body of evidence suggests that anhedonia is, at least partially, independent from depression, therefore it needs careful assessment and targeted treatment. Korean College of Neuropsychopharmacology 2023-08-31 2023-08-31 /pmc/articles/PMC10335915/ /pubmed/37424409 http://dx.doi.org/10.9758/cpn.23.1086 Text en Copyright© 2023, Korean College of Neuropsychopharmacology https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Serretti, Alessandro
Anhedonia and Depressive Disorders
title Anhedonia and Depressive Disorders
title_full Anhedonia and Depressive Disorders
title_fullStr Anhedonia and Depressive Disorders
title_full_unstemmed Anhedonia and Depressive Disorders
title_short Anhedonia and Depressive Disorders
title_sort anhedonia and depressive disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335915/
https://www.ncbi.nlm.nih.gov/pubmed/37424409
http://dx.doi.org/10.9758/cpn.23.1086
work_keys_str_mv AT serrettialessandro anhedoniaanddepressivedisorders